Ken Griffin’s Citadel Builds a Major AbbVie Position as Analysts See Further Upside

Key Takeaways

• Ken Griffin’s Citadel increased its AbbVie holdings by more than 500% during the second quarter of 2026.

• AbbVie’s valuation is above its historical norms, but its drug portfolio and progress beyond the Humira patent cliff support Wall Street’s positive outlook.

Investors often monitor market figures with strong track records for clues about promising opportunities. The latest 13F filing from Griffin’s hedge fund, Citadel, revealed a substantial second-quarter investment in AbbVie (NYSE: ABBV), with the position increasing by more than 500%. The move highlights the drugmaker’s defensive qualities, dividend record, and improving long-term growth prospects.

A defensive investment for uncertain markets

Equity indexes remain near record highs despite geopolitical conflicts, persistent inflation, and elevated leverage. JPMorgan Chase (NYSE: JPM) CEO Jamie Dimon has warned that these pressures could collide and create significant market disruptions. Healthcare has historically shown resilience because medical care remains a necessity, making AbbVie’s defensive profile one likely reason for Citadel’s increased exposure.

Source: Getty Images.

AbbVie also offers a well-above-market dividend yield of roughly 2.6%. The company belongs to the Dividend Kings group, which recognizes businesses with at least 50 consecutive years of dividend increases. AbbVie inherited part of that history through its spinoff from Abbott (NYSE: ABT), but it has raised its payout every year since becoming an independent company. That record underscores management’s commitment to returning value to shareholders.

The drugmaker’s underlying business provides another reason for investor interest. Its aesthetics division remains solid even though Botox no longer has patent protection, with brand strength continuing to matter in that market. Meanwhile, Skyrizi and Rinvoq have helped offset the loss of exclusivity for Humira, putting AbbVie on a stronger growth trajectory.

AbbVie’s acquisition of Apogee could further reinforce its pipeline. Apogee added drug candidates focused on dermatology, respiratory disease, inflammation, and immunology, expanding the company’s potential sources of future growth.

The valuation is demanding, but analysts remain optimistic

AbbVie’s price-to-sales and price-to-earnings ratios are both above their five-year averages, so the shares may not appeal to strictly value-oriented investors. Nevertheless, 25 of the 31 Wall Street analysts covering the company rate the stock a buy. Their average price target is $277, which remains above the current share price.

That analyst optimism appears consistent with Citadel’s decision to expand its position. Investors concerned about a potential market downturn may also find AbbVie’s combination of dividend growth, defensive healthcare exposure, and pipeline development worthy of closer examination.

Should investors buy AbbVie now?

AbbVie combines an attractive dividend history with a resilient business and a more promising drug pipeline. However, its above-average valuation leaves less room for execution mistakes. Investors should weigh those strengths against the company’s risks and determine whether the shares fit their financial goals and risk tolerance.

Source link